Therefore role of HDAC inhibitors in inhibiting activation of corepressors, leading to continuous expression of ER, suggested a potential therapeutic benefit for HDAC inhibitors in breast cancer in the clinic (17). Here, HDAC9 is linked to breast carcinoma.